-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amdinocillin Pivoxil in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amdinocillin Pivoxil in Urinary Tract Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amdinocillin Pivoxil in Urinary Tract Infections Drug Details: Amdinocillin pivoxil...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Miransertib Mesylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Miransertib Mesylate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Miransertib Mesylate in Solid Tumor Drug Details: Miransertib mesylate (ARQ-092) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ceftolozane Sulfate + Tazobactam Sodium) in Febrile Neutropenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ceftolozane Sulfate + Tazobactam Sodium) in Febrile Neutropenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Ceftolozane Sulfate + Tazobactam Sodium) in Febrile Neutropenia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uprosertib in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Uprosertib in Refractory Multiple Myeloma Drug Details: Uprosertib (GSK-2141795) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uprosertib in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uprosertib in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Uprosertib in Relapsed Multiple Myeloma Drug Details:Uprosertib (GSK-2141795) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Uprosertib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Uprosertib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Uprosertib in Triple-Negative Breast Cancer (TNBC) Drug Details:Uprosertib (GSK-2141795) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftobiprole Medocaril in Bacterial Endocarditis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftobiprole Medocaril in Bacterial Endocarditis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftobiprole Medocaril in Bacterial Endocarditis Drug Details: Ceftobiprole medocaril (Zeftera/Zevtera/Mabelio) a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftobiprole Medocaril in Bacteremia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftobiprole Medocaril in Bacteremia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftobiprole Medocaril in Bacteremia Drug Details: Ceftobiprole medocaril (Zeftera/Zevtera/Mabelio) a broad-spectrum cephalosporin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftobiprole Medocaril in Skin And Skin Structure Infections (SSSI) Caused By Bacteria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftobiprole Medocaril in Skin And Skin Structure Infections (SSSI) Caused By Bacteria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftobiprole Medocaril in Skin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceftobiprole Medocaril in Community-Acquired Bacterial Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ceftobiprole Medocaril in Community-Acquired Bacterial Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ceftobiprole Medocaril in Community-Acquired Bacterial Pneumonia Drug Details: Ceftobiprole medocaril...